Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial.

Background: Recurrent brain tumors are the leading cause of cancer death in children. Indoleamine 2,3-dioxygenase (IDO) is a targetable metabolic checkpoint that, in preclinical models, inhibits anti-tumor immunity following chemotherapy.

Methods: We conducted a phase I trial (NCT02502708) of the oral IDO-pathway inhibitor indoximod in children with recurrent brain tumors or newly diagnosed diffuse intrinsic pontine glioma (DIPG).

Role of novel imaging in the management of prostate cancer.

This review summarizes novel imaging in the management of prostate cancer including multiparametric MRI, PET-CT scans with different radiotracers including C-acetate, C-choline, F-choline, F sodium fluoride, prostate-specific membrane antigen, and anti-1-amino-3-[18F] fluorocyclobutane-1-carboxylic acid (fluciclovine).

Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.

Purpose: (18)F-Fluciclovine (anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid) is a novel positron emission tomography (PET)/computed tomography (CT) radiotracer that has demonstrated utility for detection of prostate cancer. Our goal is to report the initial results from a randomized controlled trial of the integration of (18)F-fluciclovine PET-CT into treatment planning for defining prostate bed and lymph node target volumes.

Methods And Materials: We report our initial findings from a cohort of 41 patients, of the first enrolled on a randomized controlled trial, who were randomized to the (18)F-fluciclovine arm.

Towards automated planning for unsealed source therapy.

The purpose of this study was to develop and validate a technique for unsealed source radiotherapy planning that combines the segmentation and registration tasks of single-photon emission tomography (SPECT) and computed tomography (CT) datasets. The segmentation task is automated by an atlas registration approach that takes advantage of a hybrid scheme using a diffeomorphic demons algorithm to warp a standard template to the patient's CT. To overcome the lack of common anatomical features between the CT and SPECT datasets, registration is achieved through a narrow band approach that matches liver contours in the CT with the gradients of the SPECT dataset.